Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YOLT 203

Next Previous
Drug Profile

YOLT 203

Alternative Names: YOLT-203

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YolTech Therapeutics
  • Class Gene therapies; Uricosurics
  • Mechanism of Action Gene expression modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria type 1
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Primary hyperoxaluria type 1
  • Preclinical Hyperuricaemia

Most Recent Events

  • 27 Feb 2025 Phase-0 for Primary hyperoxaluria type 1 (In children, In adolescents) in China (IV) (NCT06892301)
  • 25 Feb 2025 Safety and pharmacodynamics data from a phase 0 trial in Primary hyperoxaluria type 1 released by YolTech Therapeutics
  • 04 Sep 2024 YOLT 203 receives Orphan Drug status for Primary hyperoxaluria type 1 in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top